Item 2.02. Results of Operations and Financial Condition.
On August 4, 2022, Akebia Therapeutics, Inc. (the “Company”) issued a press
release announcing its financial results for the quarter ended June 30, 2022 and
commenting on certain business updates. A copy of the Company’s press release
containing this information is furnished as Exhibit 99.1 to this Current Report
on Form 8-K (“Report”) and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
On August 4, 2022, the Company issued the press release furnished as Exhibit
99.2 to this Report and incorporated herein by reference.
The information in this Report (including Item 2.02, Item 7.01, Exhibit 99.1 and
Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the Securities Act of 1933,
as amended, except as expressly set forth by specific reference in such a
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 4, 2022, issued by Akebia Therapeutics, Inc. 99.2 Press Release, dated August 4, 2022, issued by Akebia Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses